Loading...
•
Dec 31, 2024
Castle Biosciences Q4 2024 Earnings Report
Castle Biosciences reported strong revenue growth and improved profitability in Q4 2024, driven by increased test report volume across its portfolio.
Key Takeaways
Castle Biosciences delivered an outstanding fourth quarter, achieving 31% revenue growth and a significant increase in net income compared to the same period in 2023. The company also reported a substantial increase in total test reports delivered, particularly in TissueCypher Barrett's Esophagus tests.
Revenues increased by 31% to $86.3 million in Q4 2024 compared to Q4 2023.
Net income for Q4 2024 was $9.6 million, a significant improvement from a net loss of $2.6 million in Q4 2023.
Total test reports delivered in Q4 2024 increased by 19% to 24,071.
Adjusted EBITDA for Q4 2024 was $21.3 million, up from $9.4 million in Q4 2023.
Revenue by Segment
Forward Guidance
Castle Biosciences anticipates generating between $280 million and $295 million in total revenue for the full year 2025.
Positive Outlook
- Anticipated revenue guidance for 2025 is strong, indicating continued growth.
- Focus on operational excellence is expected to drive efficiency.
- Sound capital allocation remains a priority, aiming to drive stockholder value.
- Continued expansion of clinical evidence base supports test adoption.
- Strategic opportunities will be pursued to enhance long-term value.
Challenges Ahead
- Potential impact of non-coverage by Medicare for DecisionDx-SCC test.
- Subsequent study or trial results may contradict earlier findings.
- Future scalability of TissueCypher Test may be limited by infrastructure.
- Newer gastroenterology and mental health franchises may not contribute as anticipated.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...